Scientists from Stockholm, Sweden, affiliated with Karolinska Institutet and KTH Royal Institute of Technology, have reported a significant advancement in…
Read More
Tirzepatide Shows Promising Adjunct Benefits in Type 1 Diabetes Management, Meta-Analysis Presented at European Congress on Obesity Suggests
The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
Novel Stem Cell Therapy Protocol Shows Significant Promise for Type 1 Diabetes Treatment, Reversing Disease in Mice.
Scientists at the forefront of regenerative medicine, based at the esteemed Karolinska Institutet and KTH Royal Institute of Technology in…
Read More
FDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options
Sunshine Lake Pharma, Lannett Company, and its wholly owned subsidiary Lanexa Biologics have achieved a significant milestone in diabetes care…
Read More
Novo Nordisk Launches Oral Ozempic in the US, Revolutionizing Type 2 Diabetes and Cardiovascular Risk Management
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Sanofi Receives FDA Approval to Expand Tzield Use in Children as Young as One Year for Type 1 Diabetes Delay
Sanofi has secured a significant expansion of its U.S. Food and Drug Administration (FDA) approval for Tzield (teplizumab-mzwv), a groundbreaking…
Read More
Controlling diabetes without insulin injections thanks to new implant
This groundbreaking research, originating from the Massachusetts Institute of Technology (MIT), marks a significant stride toward revolutionizing the management of…
Read More
Dulaglutide Shows Promise in Stabilizing Coronary Plaques, Revolutionizing Cardiovascular Protection Beyond Diabetes Management
The intricate relationship between Type 2 diabetes (T2D) and cardiovascular health has long been a focal point of medical research.…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read MoreYOU MAY HAVE MISSED
